Q2 2023 · 13F-HR
Ally Bridge Group (NY) LLCholdings as filed
Filed 2023-08-14 · accession 0000950123-23-008083
$82.6M
Reported value
17
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 75615P103 | — | REATA PHARMACEUTICALS INC-A | $10.8M | 13.0% | 105,558 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC - ADR | $10.3M | 12.5% | 487,631 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $10.3M | 12.4% | 266,961 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $7.3M | 8.83% | 223,382 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $6.8M | 8.25% | 2,123,162 | Common | SOLE |
| N5749R100 | 2GH | MERUS NV | $5.2M | 6.35% | 199,221 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $4.8M | 5.81% | 201,752 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $4.7M | 5.65% | 91,413 | Common | SOLE |
| 56854Q200 | MRNS* | MARINUS PHARMACEUTICALS INC | $4.2M | 5.14% | 390,418 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $4.0M | 4.89% | 800,000 | Common | SOLE |
| 74006W108 | — | PRAXIS PRECISION MEDICINES I | $3.7M | 4.46% | 3,200,000 | Common | SOLE |
| 471871103 | — | JASPER THERAPEUTICS INC | $3.4M | 4.18% | 2,517,232 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $2.9M | 3.52% | 914,630 | Common | SOLE |
| 58406B103 | — | MEDAVAIL HOLDINGS INC | $1.4M | 1.75% | 5,894,897 | Common | SOLE |
| 58286E102 | — | MDXHEALTH SA-ADR | $1.2M | 1.44% | 349,552 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $1.0M | 1.27% | 653,396 | Common | SOLE |
| 75340L104 | RPID | RAPID MICRO BIOSYSTEMS INC-A | $403,284 | 0.49% | 403,284 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.